Neopharm Glioblastoma Drug Will Require Another Phase III Study, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision by agency to require another trial of cintredekin besudotox comes after the pivotal Phase III PRECISE study failed to meet its primary endpoint.